Literature DB >> 6800956

Experimental Candida albicans, Staphylococcus aureus, and Streptococcus faecalis pyelonephritis in diabetic rats.

L Raffel, P Pitsakis, S P Levison, M E Levison.   

Abstract

Pyelonephritis was studied after an intravenous injection of Candida albicans, Staphylococcus aureus, or enterococcus in alloxan-diabetic rats and in water-diuresing or non-diuresing nondiabetic rats. The renal microbial populations of C. albicans or S. aureus were found to be greater than 10(5) colony-forming units per g for up to 42 days in diabetic rats, whereas the kidneys tended to become sterile in nondiabetic rats. No significant difference was found in the course of enterococcal pyelonephritis in diabetic versus control rats. The difference in the 50% infective dose for each microorganism between diabetic and control rats was less than or equal to log10. Neither duration of diabetes nor weight loss contributed to the greater and more sustained renal populations of C. albicans and S. aureus in diabetic rats. The inflammatory reaction in kidneys infected with S. aureus or C. albicans was greater in diabetic rats. Fungus balls associated with ureteral obstruction and gross multiple renal abscesses occurred in diabetic, but not in nondiabetic, rats infected with Candida. Growth of C. albicans and S. aureus in vitro in urine from diabetic rats was significantly greater than it was in urine from control rats. Addition of water or glucose to the urine of non-diuresing, nondiabetic rats significantly increased in vitro growth of S. aureus and C. albicans. These studies demonstrate greater severity of infection in the diabetic kidney due to S. aureus and C. albicans, which can be partially explained by decreased inhibitory activity of urine for these organisms in diabetic rats.

Entities:  

Mesh:

Year:  1981        PMID: 6800956      PMCID: PMC350938          DOI: 10.1128/iai.34.3.773-779.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Cellular immunity in pyelonephritis: identification of suppressor cell activity of spleen cells in response to concanavalin A and inhibition of lymphocyte-mediated L cell cytotoxicity.

Authors:  T W Williams; A M Friedlander; J M Lyons; A I Braude
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  PREVENTION OF PYELONEPHRITIS BY WATER DIURESIS: EVIDENCE FOR THE ROLE OF MEDULLARY HYPERTONICITY IN PROMOTING RENAL INFECTION.

Authors:  V T ANDRIOLE; F H EPSTEIN
Journal:  J Clin Invest       Date:  1965-01       Impact factor: 14.808

3.  The effects of alloxan diabetes on phagocytosis and susceptibility to infection.

Authors:  K F WERTMAN; M R HENNEY
Journal:  J Immunol       Date:  1962-09       Impact factor: 5.422

4.  Experimental mucormycosis (Rhizopus infection) in mice; the failure of chronic alloxan diabetes to modify host susceptibility.

Authors:  R A SCHOFIELD; R D BAKER
Journal:  AMA Arch Pathol       Date:  1956-05

5.  Candida albicans infection in alloxan induced diabetic mice.

Authors:  A K Mukherji; K C Mallik
Journal:  Indian J Med Res       Date:  1975-04       Impact factor: 2.375

6.  A study of subcutaneous staphylococcal infection in alloxan diabetic mice.

Authors:  U Sood; D S Agarwal; A L Aurora
Journal:  Indian J Med Res       Date:  1975-11       Impact factor: 2.375

7.  Altered host response to experimental pyelonephritis in alloxan diabetic rats.

Authors:  J A Coil; J H Davis
Journal:  J Surg Res       Date:  1967-01       Impact factor: 2.192

8.  Streptozotocin-induced diabetes mellitus and the host-parasite relation in murine schistosomiasis mansoni.

Authors:  A A Mahmoud; A W Cheever; K S Warren
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

9.  Modification by suppressor cells and serum factors of the cell-mediated immune response in experimental pyelonephritis.

Authors:  T Miller; L Scott; E Stewart; D North
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

10.  Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunologic responses. Granuloma formation, delayed dermal reactivity and allograft rejection.

Authors:  A A Mahmoud; H M Rodman; M A Mandel; K S Warren
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

View more
  8 in total

1.  Constituents of human urine alter siderophore production of Escherichia coli.

Authors:  S Sharma; N Puri; R Gupta
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

2.  Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.

Authors:  M A Fisher; P G Lee; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  Resistance and susceptibility to infection in inbred murine strains. III. Effect of thymosin on cellular immune responses of alloxan diabetic mice.

Authors:  S B Salvin; E P Tanner
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

4.  Effects of garlic extract treatment in normal and streptozotocin diabetic rats infected with Candida albicans.

Authors:  M Bokaeian; A Nakhaee; Bita Moodi; A Farhangi; Azim Akbarzadeh
Journal:  Indian J Clin Biochem       Date:  2010-05-27

5.  Renal candidiasis in the rat: effects of ureteral obstruction and diabetes.

Authors:  W F Tarry; T S Kowalkowski; M A Fisher
Journal:  Urol Res       Date:  1989

Review 6.  Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract.

Authors:  Kimberly A Kline; Amanda L Lewis
Journal:  Microbiol Spectr       Date:  2016-04

Review 7.  Targeting Gut Microbiota for the Prevention and Management of Diabetes Mellitus by Dietary Natural Products.

Authors:  Bang-Yan Li; Xiao-Yu Xu; Ren-You Gan; Quan-Cai Sun; Jin-Ming Meng; Ao Shang; Qian-Qian Mao; Hua-Bin Li
Journal:  Foods       Date:  2019-09-25

8.  Virulence factors of uropathogens and their role in host pathogen interactions.

Authors:  Deenadayalan Karaiyagowder Govindarajan; Kumaravel Kandaswamy
Journal:  Cell Surf       Date:  2022-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.